Candesic advises Everlight Radiology on AUD1bn acquisition by Radiology Partners
Candesic has provided AI vendor commercial due diligence to Everlight Radiology in support of its AUD1bn acquisition by Radiology Partners, the leading provider of technology and AI-enabled radiology services in the US. The transaction will bring together Everlight’s international teleradiology network with Radiology Partners’ vRad platform, creating a leading global teleradiology business. The combination will connect the organisations’ technology, clinical…
Candesic advises ARCHIMED on investment in Renata Medical
Paediatric medical device company Renata Medical has just closed a $25m Series D financing round. The round was led by global private equity investment firm ARCHIMED Candesic is delighted to have supported ARCHIMED with commercial due diligence on the investment in Renata, a US-based technology company focused on developing cardiovascular devices specifically for children with congenital heart disease. The Candesic…
argenx to acquire Forte Biosciences for $2.2bn
Dutch-Belgian immunology group argenx SE has entered a definitive agreement to acquire US-based biopharma group Forte Biosciences in an all-cash transaction valued at approximately $2.2bn. This deal, the largest in the history of the Euronext-listed firm, marks a significant pivot as argenx seeks to diversify its portfolio beyond its flagship blockbuster treatment, Vyvgart. Under the terms of the agreement, argenx…
Healthcare Activos launches new hospital platform
Healthcare Activos launched its newest strategic vehicle, Healthcare Activos Hospitals, on Tuesday, July 22. Created in partnership with a group of long term institutional investors, the platform has an initial investment target of €800m. The platform has acquired three hospitals in Portugal from Praemia REIM and Icade for a total transaction value, including planned expansion capital, of up to €250…
Ardian takes majority control of Pflegia
Global private investment firm Ardian is acquiring a majority stake in Berlin-based digital healthcare recruitment platform Pflegia. Founded in 2019, Pflegia operates an AI powered reverse recruiting platform that connects healthcare professionals with care providers by matching candidate preferences with institutional needs. This transaction marks a significant move for Ardian Growth, the specialist team within the firm that focuses on…
Inflexion expands DACH portfolio with Primed
European middle market private equity firm Inflexion is acquiring Primed Group from DACH focused private equity firm Paragon Partners. The transaction, which is being executed through Inflexion’s Buyout Fund VI, marks the firm’s sixth investment in the DACH region. The financial terms of the deal remain undisclosed, and the transaction is subject to customary regulatory approvals. The acquisition highlights the…
Spire takeover extended as £1.3bn property deal completes
Spire Healthcare has been the focus of two major transactions, with Toscafund’s potential £1.01bn takeover bid extended to August 6, while Blue Owl Capital has completed a £1.3bn acquisition of 12 Spire hospital properties. Toscafund Asset Management is the company’s second largest shareholder. It submitted a non-binding proposal in May 2026 to acquire the remaining 82 per cent of the…
Cygnet enters Irish market with Orchard Care acquisition
UK-based health and social care services specialist Cygnet Group has entered the Republic of Ireland market with the acquisition of Orchard Care Group. The transaction which completed on Wednesday, July 8 marks a major milestone in the ongoing expansion programme for the UK based provider. Through this deal, Cygnet inherits a substantial portfolio consisting of thirty-nine residential and community homes…
EQT targets surgical technology with Corza Biosurgery deal
Global investment firm EQT is to acquire the biosurgery business unit from Chicago-based private equity firm GTCR’s portfolio company, Corza Medical. Financial details of the transaction remain undisclosed. The deal, through the EQT X fund, is expected to close in Q4 2026, subject to regulatory clearances and customary closing conditions. The divestiture represents a significant corporate carve-out for Corza Medical. Under…
Novartis buys Myricx Bio in $1.5bn deal
Swiss drug and health care company Novartis has acquired London based biotech Myricx Bio in a deal valued at up to $1.5bn Announced on July 6, the deal comprises a substantial $1.1bn upfront cash payment and $400 million in potential milestones. The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals. Myricx Bio…